These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33971361)

  • 1. Persistence of asthma biologic use in a US claims database.
    Maddux JT; Inselman JW; Jeffery MM; Lam RW; Shah ND; Rank MA
    Ann Allergy Asthma Immunol; 2021 Dec; 127(6):648-654. PubMed ID: 33971361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asthma Patients Who Stop Asthma Biologics Have a Similar Risk of Asthma Exacerbations as Those Who Continue Asthma Biologics.
    Jeffery MM; Inselman JW; Maddux JT; Lam RW; Shah ND; Rank MA
    J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2742-2750.e1. PubMed ID: 33652135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to Asthma Biologics: Implications for Patient Selection, Step Therapy, and Outcomes.
    Maddux JT; Inselman JW; Jeffery MM; Lam RW; Shah ND; Rank MA
    Chest; 2021 Mar; 159(3):924-932. PubMed ID: 33558205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and economic burden of severe asthma among US patients treated with biologic therapies.
    Reibman J; Tan L; Ambrose C; Chung Y; Desai P; Llanos JP; Moynihan M; Tkacz J
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):318-325.e2. PubMed ID: 33775904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of mepolizumab on exacerbations in severe asthma: Results from a U.S. insurance claims data base.
    Ortega H; Hahn B; Bogart M; Bell CF; Bancroft T; Chastek B; Llanos JP
    Allergy Asthma Proc; 2020 Sep; 41(5):341-347. PubMed ID: 32867888
    [No Abstract]   [Full Text] [Related]  

  • 6. Asthma biologic trial eligibility and real-world outcomes in the United States.
    Lam RW; Inselman JW; Jeffery MM; Maddux JT; Shah ND; Rank MA
    J Asthma; 2022 Dec; 59(12):2352-2359. PubMed ID: 34818955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe asthma exacerbations in the United States:: Incidence, characteristics, predictors, and effects of biologic treatments.
    Trevor J; Lugogo N; Carr W; Moore WC; Soong W; Panettieri RA; Desai P; Trudo F; Ambrose CS
    Ann Allergy Asthma Immunol; 2021 Nov; 127(5):579-587.e1. PubMed ID: 34273485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies.
    Hansen S; Baastrup Søndergaard M; von Bülow A; Bjerrum AS; Schmid J; Rasmussen LM; Johnsen CR; Ingebrigtsen T; Håkansson KEJ; Johansson SL; Bisgaard M; Assing KD; Hilberg O; Ulrik C; Porsbjerg C
    Chest; 2024 Feb; 165(2):253-266. PubMed ID: 37925144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asthma biologics: Real-world effectiveness, impact of switching biologics, and predictors of response.
    Abbas F; Georas S; Cai X; Khurana S
    Ann Allergy Asthma Immunol; 2021 Dec; 127(6):655-660.e1. PubMed ID: 34481992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Burden of asthma exacerbations and health care utilization in pediatric patients with asthma in the US and England.
    Gokhale M; Hattori T; Evitt L; Lenney W; Nordstrom B; Collins J; Schultze A; Van Dyke MK
    Immun Inflamm Dis; 2020 Jun; 8(2):236-245. PubMed ID: 32222038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Effectiveness of Reslizumab in Patients With Severe Eosinophilic Asthma - First Initiators and Switchers.
    Hashimoto S; Kroes JA; Eger KA; Mau Asam PF; Hofstee HB; Bendien SA; Braunstahl GJ; Broeders MEAC; Imming LM; Langeveld B; Maitland-van der Zee AH; Oud KTM; Patberg KW; Smeenk FWJM; Romme EAPM; van Bezouw MJ; van de Ven MJ; van Veen A; van Velzen E; van Veen IHPAA; Weersink EJM; Ten Brinke A; Sont JK; Bel EH;
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2099-2108.e6. PubMed ID: 35487369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease burden in patients with asthma before initiating biologics: A retrospective cohort database study.
    Ortega H; Hahn B; Tran JN; Bell C; Shams SA; Llanos JP
    Allergy Asthma Proc; 2019 May; 40(3):146-153. PubMed ID: 30925945
    [No Abstract]   [Full Text] [Related]  

  • 13. Prior authorization delays biologic initiation and is associated with a risk of asthma exacerbations.
    Dudiak GJ; Popyack J; Grimm C; Tyson S; Solic J; Ishmael FT
    Allergy Asthma Proc; 2021 Jan; 42(1):65-71. PubMed ID: 33404389
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: To biologic or not to biologic?
    Anderson WC; Szefler SJ
    Ann Allergy Asthma Immunol; 2019 Apr; 122(4):367-372. PubMed ID: 30703438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic use and outcomes among adults with severe asthma treated by US subspecialists.
    Panettieri RA; Ledford DK; Chipps BE; Soong W; Lugogo N; Carr W; Mohan A; Carstens D; Genofre E; Trudo F; Ambrose CS
    Ann Allergy Asthma Immunol; 2022 Oct; 129(4):467-474.e3. PubMed ID: 35728746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world impact of mepolizumab in patients with life-threatening asthma: US insurance claims database analysis.
    Silver J; Molfino N; Bogart M; Packnett ER; McMorrow D; Wu J; Hahn B
    Clin Ther; 2021 Dec; 43(12):2064-2073. PubMed ID: 34893348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends and Disparities in Asthma Biologic Use in the United States.
    Inselman JW; Jeffery MM; Maddux JT; Shah ND; Rank MA
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):549-554.e1. PubMed ID: 31472294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use.
    Jackson DJ; Burhan H; Menzies-Gow A; Pfeffer P; Nanzer A; Garcia Gil E; Morris T; Tran TN; Hirsch I; Dube S
    J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1534-1544.e4. PubMed ID: 35202871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world patterns and implications of short-acting β
    Lugogo N; Gilbert I; Tkacz J; Gandhi H; Goshi N; Lanz MJ
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):681-689.e1. PubMed ID: 33515710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prediction model for asthma exacerbations after stopping asthma biologics.
    Inselman JW; Jeffery MM; Maddux JT; Lam RW; Shah ND; Rank MA; Ngufor CG
    Ann Allergy Asthma Immunol; 2023 Mar; 130(3):305-311. PubMed ID: 36509405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.